Compare LCNB & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | EBS |
|---|---|---|
| Founded | 1877 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 303.3M |
| IPO Year | 1999 | 2006 |
| Metric | LCNB | EBS |
|---|---|---|
| Price | $19.14 | $5.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.83 | $10.00 |
| AVG Volume (30 Days) | 16.2K | ★ 946.0K |
| Earning Date | 10-15-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | 68.04 | ★ 125.83 |
| EPS | ★ 1.35 | N/A |
| Revenue | $6,445,000.00 | ★ $742,900,000.00 |
| Revenue This Year | $11.08 | N/A |
| Revenue Next Year | $0.51 | $7.03 |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.83 | $4.36 |
| 52 Week High | $21.32 | $14.06 |
| Indicator | LCNB | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 28.74 |
| Support Level | $18.33 | $4.36 |
| Resistance Level | $19.35 | $7.18 |
| Average True Range (ATR) | 0.40 | 0.44 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 7.28 | 5.88 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.